Figure 4.

Sensitivity analyses assessing the comparative effectiveness and safety of rivaroxaban and warfarin according to eGFR category.^a (A) As-treated analysis in which patients were censored on oral anticoagulant treatment switches or discontinuation; (B) Analysis adjusted for baseline eGFR category and variables observed to be meaningfully imbalanced when covariate balance was assessed in each eGFR category; (C) Analysis in which the occurrence of study outcome events were identified using both hospital and emergency department data (in participating sites where emergency department data were available) and (D) Analysis in which the comparative effectiveness outcome additionally included myocardial infarction.

^aThe percentage of variability across sites attributable to heterogeneity beyond chance were estimated using the I² statistic where values of ≤25%, >25% to 75%, and >75% correspond to low, moderate, and high levels of heterogeneity, respectively.